TAM February/March 2023 CME Posttest
Continuing Medical Education Posttest
The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:
February/March 2023, Volume 31, Issue 1
- CME Credit Available: 3.0 AMA PRA Category 1 Credits™
- Release Date: March 31, 2023
- Expiration Date: March 31, 2024
To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.
On completion of this activity, the learner will be able to:
- Describe the synthetic production and potential of bacteriophages in the battle against antimicrobial resistance.
- Deliver affirming, respectful health care in HIV treatment and prevention settings when caring for transgender and gender-diverse individuals.
- List current recommendations for prevention of hepatitis B virus infection among people with HIV.
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians in the evolving challenges of managing HIV and other viral infections.
This enduring material is designed for physicians who are actively involved in the medical care of people with HIV and other viral infections.
This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is offered from March 31, 2023 to March 31, 2024. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.
Disclosure of Financial Interests
Dr Van Gerwen has received research grant support to her institution from Gilead Sciences, Inc, and Abbott Molecular, Inc; she has served on a scientific advisory board for Scynexis. Dr Blumenthal has received research support paid to her institution from Gilead Sciences, Inc. (Updated 11/28/22)
Dr Corcorran has no relevant financial relationships to disclose. Dr Kim has received funding paid to her institution from Gilead Sciences, Inc. (Updated 11/15/22)
Dr Schooley has served as a consultant to LyseNtech, GSK, and AbbVie, and served on data safety monitoring boards for VIR and Merck (Updated 03/22/23)
Planner 1 has served as a consultant or received advisor fees from Antiva, Assembly Biosciences, Generate Biomedicines, and IGM Biosciences, and received fees for participation in review activities, eg, data monitoring boards, statistical analysis, or endpoint adjudication committees with Gilead Sciences, Inc. (Updated 3/30/23)
Planners 2 and 3 have no relevant financial relationships with ineligible companies to disclose.
Topics in Antiviral Medicine Editorial Board
Dr Richman has served as a consultant or received advisor fees from Antiva, Assembly Biosciences, Generate Biomedicines, and IGM Biosciences, and received fees for participation in review activities, eg, data monitoring boards, statistical analysis, or endpoint adjudication committees with Gilead Sciences, Inc. (Updated 3/30/23
Dr Benson has served on advisory and data safety monitoring boards for GlaxoSmithKline/ViiV Healthcare, received research grants awarded to her institution from Gilead Sciences, Inc., and serves as a consultant to NDA Partners, LLC. (Updated 7/08/22)
Dr Hirsch has no relevant financial relationships with ineligible companies to disclose. (Updated 4/27/22)
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:
Independent educational grants for the 2023 Improving the Management of HIV Disease® CME program:
Gilead Sciences, Inc
Merck & Co, Inc
Drug and Product Disclaimer
This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
The views and opinions expressed herein are those of faculty and do not necessarily represent the opinions or recommendations of IAS–USA.
If you have any questions about this activity, please contact the IAS–USA:
Mail: 131 Steuart St, Ste 500, San Francisco, CA 94105
Phone: (415) 544-9400
By clicking the link below, I acknowledge that I have read these instructions and understand them.
You must log in to take the activity.